Research Group on Myeloid Neoplasms
Oncology Area
Analyse of the risk factors for thrombosis in myelofibrosis
Analyse patients diagnosed with myelodysplasticsyndromes with 20q deletion and del(20q). Assess the incidence, prognostic value and impact on response to azacitidine
Analyse in patients diagnosed of acute myeloid leukemias and del(7q) the incidence, prognostic value and potential as a therapeutic target of chromosomal deletions of the EZH2 gene and of genetic mutations alterations and other genetic mutations
Coordinatora
STAFF
Collaborating Researchers
Carlos Carretero MárquezMontserrat Gómez Calafat
Nurse
Mª Carmen Hurtado Fontelles
Technicians
Administrative assistant
Publications
Genomic classification and outcomes of young patients with polycythemia vera and essential thrombocythemia according to the presence of splanchnic vein thrombosis and its chronology. Garrote M, López-Guerra M, García-Pagán JC, Arellano-Rodrigo E, Ferrer-Marín F, Hernández-Boluda JC, Bellosillo B, Nomdedeu M, Hernández-Gea V, Triguero A, Guijarro F, Álamo J, Baiges A, Turon F, Colomer D, Cervantes F, Alvarez-Larrán A. Annals of Hematology. 2024 Jan 24. doi: 10.1007/s00277-023-05610-x. PMID: 38263537.
Outcomes after intensive chemotherapy for secondary and myeloidrelated changes acute myeloid leukemia patients aged 60 to 75 years old: a retrospective analysis from the PETHEMA registry. Martinez-Cuadron D, Megias-Vericat J, Gil C, Bernal T, Tormo M, Martinez-Sanchez P, Rodriguez-Medina C, Serrano J, Herrera P, Simon J, Sayas M, Bergua J, Lavilla-Rubira E, Amigo M, Benavente C, Lorenzo J, Perez-Encinas M, Vidriales M, Colorado M, De Rueda B, Garcia-Boyero R, Marini S, Garcia-Suarez J, Lopez-Pavia M, Gomez-Roncero M, Noriega V, Lopez A, Labrador J, Cabello A, Sossa C, Algarra L, Stevenazzi M, Solana-Altabella A, Boluda B, Montesinos P. Haematologica. 2024 Jan 1;109(1):115-128. doi: 10.3324/haematol.2022.282506. PMID: 37199127
Outcomes and effect of somatic mutations after erythropoiesis stimulating agents in patients with lower-risk myelodysplastic syndromes. Caballero J, Dávila J, López-Pavía M, Such E, Bernal T, Ramos F, Calabuig M, Sánchez J, Pomares H, Barba M, Abáigar M, González B, Merchán B, Sancho-Tello R, Callejas M, Muñoz-Novas C, Cerveró C, Sanz G, Rivas J, Campelo M. Therapeutic Advances in Hematology. 2024 Jan 4:15:20406207231218157. doi: 10.1177/20406207231218157. PMID: 38186638
Single agent subcutaneous blinatumomab for advanced acute lymphoblastic leukemia. Jabbour E, Zugmaier G, Agrawal V, Martínez-Sánchez P, Roca J, Cassaday R, Böll B, Rijneveld A, Abdul-Hay M, Huguet F, Cluzeau T, Díaz M, Vucinic V, González-Campos J, Rambaldi A, Schwartz S, Berthon C, Hernández-Rivas J, Gordon P, Brüggemann M, Hamidi A, Chen Y, Wong H, Panwar B, Katlinskaya Y, Markovic A, Kantarjian H. American Journal of Hematology. 2024 Feb 5. doi: 10.1002/ajh.27227. PMID: 38317420
A simple prognostic system in myelofibrosis patients undergoing allogeneic stem cell transplant: a CIBMTR/EBMT analysis. Tamari R, McLornan D, Ahn K, Estrada-Merly N, Hernandez-Boluda J, Giralt S, Palmer J, Gale R, DeFilipp Z, Marks D, van der Poel M, Verdonck L, Battiwalla M, Diaz M, Gupta V, Ali H, Litzow M, Lazarus H, Gergis U, Bashey A, Liesveld J, Hashmi S, Pu J, Beitinjaneh A, Bredeson C, Rizzieri D, Savani B, Abid M, Ganguly S, Agrawal V, Ulrike V, Wirk B, Jain T, Cutler C, Aljurf M, Kindwall-Keller T, Kharfan-Dabaja M, Hildebrandt G, Pawarode A, Solh M, Yared J, Grunwald M, Nathan S, Nishihori T, Seo S, Scott B, Nakamura R, Oran B, Czerw T, Yakoub-Agha I, Saber W. Blood Advances. 2023 Aug 8;7(15):3993-4002. doi: 10.1182/bloodadvances.2023009886. PMID: 37134306
Adoptive immunotherapy via donor lymphocyte infusions following allogeneic hematopoietic stem cell transplantation for myelofibrosis: a real-world, retrospective multicenter study. Rampotas A, Sockel K, Panitsas F, Theuser C, Bornhauser M, Hernani R, Hernandez-Boluda JC, Esquirol A, Avenoso D, Tsirigotis P, Robin M, Czerw T, Helbig G, Roddie C, Lambert J, McLornan DP. Transplantation and Cellular Therapy. 2023 Nov;29(11):687.e1-687.e7. doi: 10.1016/j.jtct.2023.08.020. PMID: 37633414
Allogeneic hematopoietic cell transplantation in patients with CALR-mutated myelofibrosis: a study of the Chronic Malignancies Working Party of EBMT. Hernandez-Boluda J, Eikema D, Koster L, Kroger N, Robin M, de Witte M, Finke J, Finazzi M, Broers A, Raida L, Schaap N, Chiusolo P, Verbeek M, Hazenberg C, Halaburda K, Kulagin A, Labussiere-Wallet H, Gedde-Dahl T, Rabitsch W, Raj K, Drozd-Sokolowska J, Battipaglia G, Polverelli N, Czerw T, Yakoub-Agha I, Mclornan D. Bone Marrow Transplantation. 2023 Dec;58(12):1357-1367. doi: 10.1038/s41409-023-02094-1. PMID: 37679647
Application of IPSET-thrombosis in 1366 patients prospectively followed from the Spanish Registry of essential thrombocythemia. Alvarez-Larrán A, Cuevas B, Velez P, Noya S, Caballero-Navarro G, Ferrer-Marín F, Carbonell S, Pérez-Encinas M, Gómez-Casares M, Pérez-López R, Magro E, Moretó A, Pastor-Galán I, Angona A, Mata-Vázquez M, Guerrero-Fernández L, Guerra J, Carreño-Tarragona G, Fox L, Murillo I, García-Gutiérrez V, Mora E, Stuckey R, Arellano-Rodrigo E, Hernández-Boluda J, Pereira A, MPN Spanish Grp GEMFIN. Hemasphere. 2023 Jul 18;7(8):e936. doi: 10.1097/HS9.0000000000000936. PMID: 37476303
A randomized phase 2 trial of azacitidine with or without durvalumab as first-line therapy for higher-risk myelodysplastic syndromes. Zeidan AM, Boss I, Beach CL, Copeland WB, Thompson E, Fox BA, Hasle VE, Ogasawara K, Cavenagh J, Silverman LR, Voso MT, Hellmann A, Tormo M, O’Connor T, Previtali A, Rose S, Garcia-Manero G. Blood Advances. 2022 Apr 12;6(7):2207-2218. doi: 10.1182/bloodadvances.2021005487. PMID: 34972214
A randomized phase 2 trial of azacitidine with or without durvalumab as first-line therapy for older patients with AML. Zeidan AM, Boss I, Beach CL, Copeland WB, Thompson E, Fox BA, Hasle VE, Hellmann A, Taussig DC, Tormo M, Voso MT, Cavenagh J, O’Connor T, Previtali A, Rose S, Silverman LR. Blood advances. 2022 Apr 12;6(7):2219-2229. doi: 10.1182/bloodadvances.2021006138. PMID: 34933333
Acute leukemia arising from myeloproliferative or myelodysplastic/myeloproliferative neoplasms: a series of 372 patients from the PETHEMA AML registry. Hernandez Boluda JC, Martinez Cuadron D, Pereira A, Rodriguez Veiga R, Boluda B, Gil C, Casal-Marini S, Serrano J, Martinez Lopez J, Bergua J, Algarra L, Bernal T, Lopez Lorenzo JL, Colorado M, Lopez A, Tormo M, Sayas MJ, Trigo F, Lopez Pavia M, Perez Simon JA, Lavilla Rubira E, Rodriguez Medina C, Rodriguez Gutierrez JI, Sanz Caballer MA, Montesinos P. Leukemia Research. 2022 Mar 6;115:106821. doi: 10.1016/j.leukres.2022.106821. PMID: 35286939
Allogeneic hematopoietic cell transplantation in patients with myeloid/lymphoid neoplasm with FGFR1-rearrangement: a study of the Chronic Malignancies Working Party of EBMT. Hernandez-Boluda J, Pereira A, Zinger N, Gras L, Martino R, Paneesha S, Finke J, Chinea A, Rambaldi A, Robin M, Saccardi R, Natale A, Snowden J, Tsirigotis P, Vallejo C, Wulf G, Xicoy B, Russo D, Maertens J, Daguindau E, Lenhoff S, Hayden P, Czerw T, McLornan D, Yakoub-Agha I. Bone Marrow Transplantation. 2022 Mar;57(3):416-422. doi: 10.1038/s41409-021-01553-x. PMID: 35066569
Adverse prognostic impact of complex karyotype (≥3 cytogenetic alterations) in adult T-cell acute lymphoblastic leukemia (T-ALL). Genesca E, Morgades M, Gonzalez-Gil C, Fuster-Tormo F, Haferlach C, Meggendorfer M, Montesinos P, Barba P, Gil C, Coll R, Moreno MJ, Martinez-Carballeira D, Garcia-Cadenas I, Vives S, Ribera J, Gonzalez-Campos J, Diaz-Beya M, Mercadal S, Artola MT, Cladera A, Tormo M, Bermudez A, Vall-Llovera F, Martinez-Sanchez P, Amigo ML, Monsalvo S, Novo A, Cervera M, Garcia-Guinon A, Ciudad J, Cervera J, Hernandez-Rivas JM, Granada I, Haferlach T, Orfao A, Sole F, Ribera JM. Leukemia Research. 2021 Jun 8;109:106612. doi: 10.1016/j.leukres.2021.106612. PMID: 34139642
Allogeneic haematopoietic cell transplantation for myelofibrosis: proposed definitions and management strategies for graft failure, poor graft function and relapse: best practice recommendations of the EBMT Chronic Malignancies Working Party. McLornan D, Boluda J, Czerw T, Cross N, Deeg H, Ditschkowski M, Moonim M, Polverelli N, Robin M, Aljurf M, Conneally E, Hayden P, Yakoub-Agha I. Leukemia. 2021 Sep;35(9):2445-2459. doi: 10.1038/s41375-021-01294-2. PMID: 34040148
Allogeneic hematopoietic cell transplantation in older myelofibrosis patients: a study of the Chronic Malignancies Working Party of EBMT and the Spanish Myelofibrosis Registry. Hernandez-Boluda JC, Pereira A, Kroger N, Cornelissen JJ, Finke J, Beelen D, de Witte M, Wilson K, Platzbecker U, Sengeloev H, Blaise D, Einsele H, Sockel K, Kruger W, Lenhoff S, Salaroli A, Martin H, Garcia-Gutierrez V, Pavone V, Alvarez-Larran A, Raya JM, Zinger N, Gras L, Hayden P, Czerw T, McLornan D, Yakoub-Agha I. American Journal of Hematology. 2021 Oct 1;96(10):1186-1194. doi: 10.1002/ajh.26279. PMID: 34152630
An investigation of the potential association between gastrointestinal viral and bacterial infection and development of intestinal acute graft versus host disease following allogeneic hematopoietic stem cell transplantation. Bueno F, Albert E, Gimenez E, Pinana J, Perez A, Gomez M, Hernandez-Boluda J, Gonzalez-Barbera E, Montoro J, Buesa J, Guerreiro M, Balaguer-Rosello A, Hernani R, Sanz J, Solano C, Navarro D. Journal of Medical Virology. 2021 Aug;93(8):4773-4779. doi: 10.1002/jmv.26892. PMID: 33605457
Projects
Title: Factores clinicobiológicos y genéticos asociados al riesgo de trombosis en la mielofibrosis
Funding body: Instituto de Salud Carlos III – Cofinanciado FEDER
Principal Investigator: Juan Carlos Hernández Boluda
Duration: 2022 – 2024
Total budget: 96.800 €
Title: Molecular characterisation with NGS of patients with essential thrombocythaemia or polycythaemia vera who develop resistance to hydroxycarbamide according to the European LeukemiaNet criteria
Funding body: Gilead Fellowship Program
Principal Investigator: José V. Cervera Zamora
Duration: 2018 – 2019
Total budget: 49.657 €
+ Info
Doctoral candidate: Calabuig Muñoz, Marisa
Director(s): Tormo Díaz, Mar; Solano Vercet, Carlos
Date of the defense: 04/05/2022
University: Universitat de València
Title: Rol del complejo RUNX1-CBF-Β/HIPK2/p300/p53 en la evolución leucémica de las neoplasias mieloproliferativas crónicas
Doctoral candidate: Lozano Asencio, Carlos Alberto
Director(s): Hernández Boluda, Juan Carlos; Climent Bataller, Joan
Date of the defense: 14/02/2020
University: Universitat de València
Title: Caracterización molecular de la anemia refractaria con sideroblastos en anillo mediante un panel de secuenciación de segunda generación
Doctoral candidate: Martín Castillo, Iván
Director(s): Sanz Alonso, Miguel Ángel; Such Taboada, Esperanza; Cervera Zamora, Jose Vicente
Date of the defense: 06/02/2020
University: Universitat de València
Title: Análisis de la relación coste-efectividad del tratamiento con azacitidina en pacientes con síndrome mielodisplásico en el hospital clínico universitario de valencia
Doctoral candidate: Torrecilla Junyent, Teresa
Director(s): Alós Almiñana, Manuel; Tormo Díaz, María del Mar; Cortijo Gimeno, Julio
Date of the defense: 12/06/2019
University: Universitat de València